A Comparative Study of Endoscopic Endonasal Dacryocystorhinostomy with and without Intraoperative Mitomycin-C Application

Raman Wadhera, Sat Paul Gulati, Ashok Kumar Khurana, Harikesh Sharma, Vijay Kalra, Anju Ghai

ABSTRACT

Aim: To evaluate the role of intraoperative mitomycin-C application in primary endoscopic endonasal dacryocystorhinostomy (DCR) and compare the results with conventional endoscopic endonasal DCR.

Study design: Prospective comparative interventional study.

Setting: Tertiary referral hospital.

Materials and methods: Fifty patients in the age group of 16 to 50 years presenting with symptoms and signs suggestive of nasolacrimal duct blockage refractory to conventional medical treatment were included in the study. They were assigned randomly into two groups of 25 patients each. Group A patients underwent endoscopic endonasal DCR followed by application of mitomycin-C, Group B patients underwent endoscopic endonasal DCR without application of mitomycin-C. The two groups were compared with regard to success rate and complications. The main outcome measures for success were the resolution of epiphora and patency with lacrimal irrigation.

Results: After 1 year, 24 patients (96%) in each group had complete relief from their symptoms while one patient (4%) had no relief. Syringing was patent in 24 patients (96%) in each group and blocked in one patient (4%) after 1 year of surgery.

Conclusion: The present study did not show any additional benefit of using mitomycin-C at the stoma site after primary endoscopic endonasal DCR in terms of success rate.

Keywords: Dacryocystorhinostomy, Endoscopic, Mitomycin-C, Syringing.


Source of support: Nil
Conflict of interest: None

INTRODUCTION

Commonest cause of epiphora is obstruction in the drainage channel of normally produced tear fluid. The obstruction can be anywhere in the drainage pathway starting from the lacrimal punctum to lower end of nasolacrimal duct. In adults, about 70% of obstruction in lacrimal drainage apparatus occurs at junction of lower end of lacrimal sac and upper end of nasolacrimal duct. In most cases of the lacrimal system obstruction, the watery discharge from the eyes gradually acquires a mucopurulent or purulent character due to superadded infections promoted by the stagnation in lacrimal sac which acts as a constant reservoir of infected material.

Obstruction of lacrimal pathways is either congenital or acquired. Congenital causes include congenital nasolacrimal duct obstruction, lacrimal fistula, congenital dacryocystocele, lacrimal duct cysts and mass lesions like meningencephalocele, capillary hemangioma, dermoid cyst, nasal glioma, lacrimal sac tumors. Acquired nasolacrimal obstruction may be primary or secondary. Primary obstructions are associated with fibroinflammatory process of unknown etiology. Secondary causes include infections, neoplasms, trauma, foreign bodies, melanin casts, dacryolithiasis, sarcoidosis, Wegener’s granulomatosis and radiation therapy. Primary acquired nasolacrimal duct obstruction is the most common cause of lacrimal obstruction in adults. Once dacryocystitis is well established, it becomes intractable, has little tendency to resolve with medical treatment, so the surgical treatment remains the only choice for management.

Endoscopic endonasal dacryocystorhinostomy (DCR) is a refinement over the external approach in that it avoids an external incision and subsequent scar formation and preserves the lacrimal pump mechanism of the orbicularis muscle. It is particularly useful in revision of external DCR cases where avoidance of an external incision and subsequent scarring gives it an advantage. Other advantages like one-stage procedure to correct associated nasal pathology, avoidance of injury to medial canthus, lesser operating time, minimal bleeding, lesser hospital stay are also there. Despite of its advantages, various causes of failure of endoscopic endonasal DCR have been mentioned.

Osteotomy closure by granulation tissue has been reported as the most important reason of failure in endoscopic DCR. Attempts have been made to improve the success rate of lacrimal surgery by using balloon catheters, stents, lasers and antimetabolites. Endoscopic balloon catheter dacryoplasty provides complete relief or substantial improvement in a significant number of patients with incomplete nasolacrimal duct obstruction. Laser-assisted DCR, performed either through an endocanalicular, transconjunctival or endonasal approach, yields the advantages of less bleeding, faster recovery and elimination of external scar.

Some surgeons have advocated the use of antimetabolites to augment DCR surgery. Fibrous tissue growth, scarring and granulation tissue formation during
the healing process decrease the created surface area of osteotomy site, leading to surgical failure. Mitomycin-C derived from *Streptomyces caespitosus* is an alkylating antibiotic. It reduces fibroblast collagen synthesis by inhibiting DNA-dependent RNA synthesis and can suppress cellular proliferation in any period of the cell cycle. When used as a topical 0.5 mg/ml solution, intraoperative application of mitomycin-C affects the wound healing process. Modulation of the wound healing response to prevent excessive scar formation can play a major role in endoscopic lacrimal surgery. The present study was conducted to evaluate the success rate and to compare the results of primary endoscopic endonasal DCR with and without intraoperative mitomycin-C applications.

**MATERIALS AND METHODS**

The study was conducted in the Departments of Otorhinolaryngology and Ophthalmology, Pt BD Sharma Postgraduate Institute of Medical Sciences, Rohtak. Fifty consecutive patients in the age group of 16 to 50 years presenting with symptoms and signs suggestive of nasolacrimal duct blockage refractory to conventional medical treatment were included in the study. They were assigned randomly into two groups of 25 patients each. Group A patients underwent endoscopic endonasal DCR followed by application of mitomycin-C. Group B patients underwent endoscopic endonasal DCR without application of mitomycin-C. Patients having the marked deviation of nasal septum on same side, chronic sinusitis, nasal polyps, severe bony deformity of lacrimal sac fossa (post-traumatic), bleeding disorders, nasal tumors and history of previous DCR were not included in the study.

Departmental board of postgraduate studies of our institute approved this entire study. Informed consent was obtained from the patients before the surgery. Patients were operated under local anesthesia. After appropriate premedication for sedation, nasal packing soaked in 4% lignocaine was placed anterior to the middle turbinate for 5 minutes. The area of lateral wall of the nose anterior, above and below the anterior attachment of middle turbinate was infiltrated with lignocaine 2% with 1:100,000 adrenaline. Both 0° and 30° endoscopes were used during surgery. A horizontal incision was made with help of sickle knife above and in front of the anterior attachment of middle turbinate and another horizontal incision was made anterior to the insertion of inferior turbinate. A vertical incision was made joining the two horizontal incisions over frontal process of maxilla. Mucoperiosteal flap was raised using Freer elevator and it was removed using Blakesley forceps. Frontal process of maxilla was identified and it was removed using Kerrison punch. Thin lacrimal bone was removed using through-cutting forceps. The bony window was further enlarged, with rongeurs or a high speed drill with a cutting burr, to a vertical dimension of at least 10 to 12 mm. The medial wall of the lacrimal sac was tented with lacrimal probe by an eye surgeon. The incision was given over the medial wall of sac using sickle knife. Ball probe was used, if required, to break adhesions between medial and lateral wall. The medial wall of sac was removed with help of through-cutting forceps. Syringing was done using normal saline to conform the patency. In group A patients, a surgical sponge soaked in 0.5 mg/ml solution of mitomycin-C was applied to the mucosal border of the rhinostomy site for 5 minutes under endoscopic visualization. Maximum care was taken in order to have all circumferential mucosa in contact with the sponge. After removal of the sponge, the area was irrigated thoroughly with saline solution and aspirated with an intranasal aspirator. A change in the color of the nasal mucosa from red to white gray was visible immediately after application. Mitomycin-C was not used in group B patients. Nasal cavity was packed with roll gauge immersed in antibiotic ointment. Pack was removed on next day. An oral antibiotic, antibiotic eye drops, saline nasal drops, steroid nasal spray and analgesic were advised to the patient in the postoperative period.

Regular follow-up of patients was done at 1st week, 6th week, 12th week and 1 year. On each visit, lacrimal irrigation and nasal endoscopy were done. The two groups were compared with regard to complications as well as success rate. The main outcome measures for success were the resolution of epiphora and patency with lacrimal irrigation. The main outcome determinants for complications were the presence or absence of delayed wound healing, wound necrosis, infection or excessive bleeding. We documented the subjective symptoms and classified them as: Complete relief, partial relief and no relief from the symptoms. Syringing was documented as: Patent, partially patent and blocked. The clinician who did syringing was blinded to information about clinical data and group of patient.

The data was subjected to Student’s t-test and χ² analyses.

**RESULTS**

In our study, the male to female ratio was 2:3 in group A and 8:17 in group B. Age of patients ranged from 16 to 50 years. The mean age was 32.4 ± 10.28 years in group A and 33.2 ± 9.30 years in group B. There was no significant difference in mean age between the two groups (p > 0.05). All the patients had unilateral nasolacrimal duct obstruction.
The commonest presenting symptom was tearing from the eyes seen in all the patients in both groups. Other symptoms noted were, purulent discharge, in 32% patients of group A and 24% of group B and swelling over the lacrimal sac, i.e. mucocele in 12% patients of group A and 8% of group B.

The duration of symptoms varied from 2 to 18 months with majority of patients in both groups presenting within 10 months of onset of symptoms. The mean duration of symptoms was found to be 8.76 ± 4.22 months in group A and 8.44 ± 3.69 months in group B. There was no significant difference in duration of symptoms between the two groups (p > 0.05).

On syringing, the nasolacrimal duct was found to be blocked in all the 50 patients.

Middle turbinate head was resected, where it was found enlarged. The middle turbinate head resection was done in five patients in group A and six patients in group B.

No nasal or gastrointestinal irritation was observed during application of mitomycin-C. During the follow-up period, no complications, such as delayed wound healing, abnormal nasal bleeding, mucosal necrosis or infection, were noted in any patient in both the groups. In group A, mild bleeding was observed in postoperative period in one patient. While in group B, two patients had mild bleeding in postoperative period. Bleeding subsided with conservative treatment in all patients.

After 1 year, 24 patients (96%) in each group had complete relief from their symptoms while one patient (4%) had no relief (p > 0.05) (Table 1). Syringing was patent in 24 patients (96%) in each group and blocked in one patient (4%) after 1 year of surgery (p > 0.05) (Table 2).

**DISCUSSION**

Mitomycin-C has been used to modulate fibrosis after glaucoma and pterygium surgery. Reports on the usefulness of mitomycin-C in DCR for preventing postoperative fibrosis and rhinostomy closure demonstrate mixed findings. Till date, only few studies are available to evaluate the role of intraoperative mitomycin-C application in endoscopic endonasal DCR.

Kao et al, Liao et al, Roozitalab et al and You and Fang evaluated the role of intraoperative mitomycin-C in external DCR. Kao et al, Liao et al, and You and Fang concluded that intraoperative mitomycin-C application was effective in increasing the success rate of external DCR surgery, whereas Roozitalab et al concluded that mitomycin-C does not change the success rate of this procedure.

Ugurbas et al performed endoscopic intranasal DCR and applied 0.5 mg/ml solution of mitomycin-C to the osteotomy site for 2.5 minutes intraoperatively. Specimens from four patients were collected during surgery and at 15 days, 1 month, 3 months and 6 months after surgery. Microscopic examination of specimens of the mitomycin-C group revealed attenuated epithelium with intracytoplasmic vacuoles. Normal epithelium without vacuoles was seen in the specimens of the control group. The control specimens had a dense and normocellular connective tissue compared with the hypocellular and looser connective tissue of the mitomycin-C treated group. They suggested that by causing a decrease in density and cellularity of mucosa, topical use of mitomycin-C may enhance the success of surgery.

Camara et al conducted a study to evaluate the role of intraoperative mitomycin-C in endonasal endoscopic laser-assisted DCR. The success rate of the mitomycin-C group was 99.2% compared with 89.6% in the control group. Their study supported the safety and efficacy of the intraoperative use of mitomycin-C. But, Zilelioglu et al did not find any change in the success rate after using intraoperative mitomycin-C in endoscopic endonasal DCR. Javate and Pamintuan noted a success rate of 98% in 117 patients who...

<table>
<thead>
<tr>
<th>Table 1: Subjective improvement in symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A (n = 25)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>No. of patients with complete relief</td>
</tr>
<tr>
<td>No. of patients with partial relief</td>
</tr>
<tr>
<td>No. of patients with no relief</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2: Objective findings (syringing)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A (n = 25)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>No. of patients with syringing patent</td>
</tr>
<tr>
<td>No. of patients with syringing partially patent</td>
</tr>
<tr>
<td>No. of patients with syringing blocked</td>
</tr>
</tbody>
</table>
underwent endonasal DCR using radiofrequency instruments for mucosa removal followed by mitomycin-C application, followed by placement of a double stent.16

In our study, male to female ratio was 2:3 in group A and 8:17 in group B. The increased incidence of dacryocystitis seen in females cannot be adequately explained. Sperkelsen and Barberan have ventured forth to attribute it to the use of cosmetics by females, especially on the rim of the lower eyelid.4 Others have proposed that the osseous nasolacrimal canal is longer and narrower in women than in men.17

We used mitomycin-C in concentration of 0.5 mg/ml for 5 minutes over the stoma site. Other authors have used it for time duration ranging from 2.5 to 30 minutes.9,10,11,13,14 Shortened period of application, for this relatively benign disease, may decrease the possible penetration of drug beyond the surgical borders.9 Intraoperative application of mitomycin-C does not cause any systemic problem since it is not absorbable from gastrointestinal tract. There were no major intraoperative and postoperative complications in our study. Thus, intraoperative use of mitomycin-C seems to be safe.

As the small size of rhinostomy lowers the success rate, large rhinostomy was created in our patients by removing thick bone of frontal process of maxilla along with thin lacrimal bone. Bony rhinostomy extended from above the middle turbinate attachment to the level of the midpoint of the maxillary line inferiorly. Lacrimal stenting was not done in any patient. All the patients had been followed up for 1 year. The average onset of ostium closure with granulation tissue formation after endoscopic endonasal DCR is reported to be 7.5 to 12.7 weeks.14 Analysis of Boush et al series also showed that the majority of the surgical failures occurred within 4 months after endoscopic surgery.5 This indicates that the critical period is 4 months after endoscopic surgery.

With all these results, it can be concluded that endoscopic endonasal DCR proves beneficial in patients of acquired nasolacrimal obstruction. The creation of the largest possible ostium minimizes the risk for subsequent stenosis and closure of the lacrimal ostium. The beneficial effect of mitomycin-C as a surgical adjunct is thought to be related to its potent inhibition of fibroblast proliferation. It is considered to increase the success rate of endoscopic endonasal DCR. But after 1 year of follow-up, the success rate was 96% in mitomycin-C group as well as in control group. Thus, our study did not show any additional benefit of using mitomycin-C at the stoma site after primary endoscopic endonasal DCR in terms of success rate.

REFERENCES


ABOUT THE AUTHORS

Raman Wadhera
Professor, Department of Otorhinolaryngology, Pt. BD Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.